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Atypical respiratory pathogens 
Pekka Saikku 
National Public Health Institute, Department in Oulu ,  Oulu ,  Finland 
The main atypical pathogens in respiratory tract infections are classified on the basis of their ability to cause atypical 
pneumonia. This is not a well-defined clinical entity, and it is evident that atypical pathogens can sometimes cause 
’typical’ pneumonias and vice versa. This emphasizes the need for microbiological diagnosis, since it affects the selection 
of proper treatment, in which p-lactam antibiotics and aminoglycosides are not effective. Moreover, mixed infections 
caused by atypical and typical pathogens together are common. At this moment rapid and sensitive diagnostic methods 
are lacking. Besides numerous viruses, the main bacterial pathogens causing atypical pneumonias are Mycoplasma 
pneumoniae, two chlamydial species, Chlamydia pneumoniae and C. psittaci, one rickettsia, Coxiella burnetti, and 
several Legionella species. The majority of these pathogens cause upper respiratory tract infections more often than 
overt pneumonias. An atypical agent, Chlamydia pneumoniae, has also been associated with chronic inflammatory 
conditions in the cardiovascular system. The most recently discovered pathogen in atypical pneumonias is a hantavirus 
causing hantavirus pulmonary syndrome. 
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INTRODUCTION 
‘Atypical pathogens’ in community-acquired respira- 
tory tract infections are purely microbiological entities: 
apart from pneumonias, where the pneumococcus is 
the leading causative agent, the overwhelming majority 
of respiratory infections are caused by ‘atypical 
pathogens’ (Table 1). The list of atypical pathogens is 
long, and the more microbial diagnostic methods are 
used, the more pathogens are found. A recent example 
comprises the hantaviruses recently found in hantavirus 
pulmonary syndrome [l]. Although pneumonia and 
pneumonic symptoms had earlier been described in 
hantavirus infections, as had pulmonary edema in 
rickettsioses [2], no one expected a hemorrhagic fever 
virus to be the causative agent in severe pneumonias. 
The use of advanced microbial diagnostic methods 
established a new disease syndrome. 
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HISTORY 
The history of atypical pathogens starts with psittacosis, 
caused by Chlamydia psittaci [3] ,  influenza viruses [4] 
and Q fever, caused by rickettsia, Coxiella burnetti [5]. 
Influenza virus continues to be a great scourge of all 
Table 1 Agents associated with atypical pneumonias 
Agent Pneumonia type 
True bacteria 
Legionella pneumophila Mostly epidemics 
Legionella spp. Uncommon 
Mycoplasma pneumoniae Common 
Coxiella burnetti Zoonosis 
Chlamydia pneumoniae Common 
Chlamydia psittaci Unconinion 
Chlamydia trachomatis Infants 
influenza A and B Common 
adenoviruses 3, 4 and 7 Common 
Common parainfluenzas 
respiratory syncytial Common 
Unconmion rhinoviruses 
rntrroviruses Uncommon 
coronaviruses Uncommon 
herpes viruses Uncommon 
Mycoplasma 
Rickettsia 
Chlamydia 
Viruses 
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mankind, and a possible appearance of a new killer 
strain is in every autumn a greater menace than the 
feared Ebola virus. The other two agents also continue 
to be important respiratory tract pathogens, but being 
zoonoses, are limited in their occurrence mostly to 
cases with animal contacts. The 1940s saw the discovery 
of Eaton-PPLO agent 161, Mycoplasma pneumoniue, 
which still is one of the commonest and well- 
recognized causes of pneumonia worldwide. Virologic 
research has revealed a long list of viral agents, ranging 
from adenoviruses, enteroviruses, parainfluenza viruses, 
respiratory syncytial viruses, rhinoviruses and corona- 
viruses finally up to hantaviruses underlying the hanta- 
virus pulmonary syndrome [I]. Viruses are by far the 
most numerous causative agents in respiratory tract 
infections with ‘atypical pathogens’, and the im- 
portance of pneumococcus is the only reason justifying 
the division between ‘typical’ and ‘atypical’ pathogens. 
CLINICAL PICTURE 
Luckily, ‘atypical pneumonias’ are usually not clinically 
severe; rather, the converse is the case. Some clinical 
features of atypical pneumonias are presented in Table 
2. In the patient history, family cases and the epi- 
demiologic situation can aid in the diagnosis, as well as 
contact with a sick parrot when there is suspicion of 
psittacosis. The onset can be delayed and insidious. 
Sputum production can be nlinimal and polymorpho- 
nuclear leukocytes are not present. In the chest X-ray, 
no lobar infiltrates, but more diffuse alterations ‘typical 
of atypical pneumonia’, are seen. Leukocytosis can be 
absent in cases without massive pulmonary destruction, 
the erythrocyte sedimentation level is usually elevated, 
but C-reactive protein does not reach the levels found 
especially in severe pneumococcal pneumonias. How- 
ever, none of these symptoms and signs readily 
differentiates an ‘atypical’ disease from a ‘typical’ one. 
AU the values overlap, and even a lobar infiltrate in the 
X-ray can be caused by an atypical pathogen [7] .  
Without proper microbial diagnosis, the first clue to the 
etiology can too often be only the lack of response to 
the standard antimicrobial treatment used. 
Table 2 Some features considered typical for atypical 
pneumonias 
Typical patient history 
Lack of purulent sputum 
Typical chest X-ray finding 
Absence of leukocytosis 
Normal or moderately elevated C-reactive protein 
Poor response to p-lactam therapy 
In the following sections the main bacterial agents 
causing atypical respiratory tract infections are dis- 
cussed, with a special emphasis on the latest bacterial 
addition, Chlamydia pneumoniae. 
Mycoplasma pneumoniae 
Mycoplasmal pneumonias concentrate in the younger 
age groups, and this is illustrated in Figure 1, comparing 
the prevalence of antibodies against M.  pneumoniae 
and Chlamydia pneumoniae in the Finnish population. 
The clinical description of mycoplasmal infections is 
classical but there are some open questions. One is the 
lack of reliable diagnostic methods, since conventional 
serologic methods, cold-agglutinin and complement- 
fixation tests, are neither sensitive nor specific, although 
the former is easy to perform. A second question is, 
how effective is the antibiotic treatment in mycoplasmal 
pneumonias? Mycoplasmal diseases in general are a 
neglected area, and we should not rely on serology only 
in the diagnosis of mycoplasmal pneumonias [8]. 
Legionella species 
The epidemic of a curious disease named afterwards as 
‘legionellosis’ in Pittsburgh in 1976 brought a special 
bacterial genus to our attention [9]. Although its first 
member had been discovered over thirty years earlier 
[lo], only then was it discovered to be the causative 
agent of several serious epidemics of respiratory in- 
fections. Relatively new also is its association with 
environmental constructions and air-conditioning tech- 
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Figure 1 Geometric mean titers (GMTs) in relation to 
age in patients with suspected viral illnesses studied at the 
Department of Virology, University of Helsinki. M.pn, 
Mycoplarma pneumoniae (58 000 samples studied); 
C.pn, Chlamydia pneumoniae (20 000 samples studied). 
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nology. The descriptions of the importance, diagnosis 
and treatment of legionellosis have become established 
[ I l l .  Over the years, at least 17 Legionella species have 
been associated with clinical diseases, especially with 
severe pneumonias, but the importance of these 
environmental bacteria varies considerably between 
different regions and settings. In some places they are 
causing a considerable proportion of all pneumonias 
[I21 and are listed among the three major causes. In 
other areas, e.g. Finland, they are, despite an intensive 
search, rarities, usually imported by tourists. 
Chlamydia psittaci 
Respiratory tract infections caused by Chlamydia psittaci 
are directly dependent on exposure to birds carrying 
the pathogen. 'Therefore, cases are seen in connection 
with curkcy and duck farming (chickens seem not to 
be iziportant), pigeon breeding, and sick pet birds. 
Casual contacts with synanthropic birds are common, 
and ruling out a bird contact is much more difficult 
than finding one. There has been a debate over whether 
Chlamydia pneumoniae is a more common agent than 
Chlamydia psittaci. Even in the microimmunofluo- 
rescence (MIF) test it is sometimes difficult to 
differentiate these two chlamydial species from each 
other [13], and it demands expertise [14]. Fortuna- 
tely, the treatment is the same in both chlamydial 
pneumonias. According to seroepidemiologic surveys, 
Chlamydia pneumoniae infections are 20-50 times more 
common than Chlamydia psitfari infections [15,16]. 
There is a possibility that the severity of Chlamydia 
psittaci infections could be due to the sensitization of 
the patient to this species by an earlier, mild Chlamydia 
pneumoniae pulmonary infection. 
Chlamydia pneumoniae 
The most recent addition to the long list of important 
atypical bacterial pathogens is Chlamydia przeumoniae. 
Like the first Legionella strains, the first strains of this 
new chlaniydial agent were isolated [17] years before an 
epidemic in northern Finland brought them to our 
attention [I 81. In the beginning, Chlamydia ptzeumoniae 
seemed to be an agent causing beiiign and mild disease, 
but later it was shown to cause-the typical feature 
of all Chlamydia-silent, slowly creeping infections, 
gradually leading to severe tissue damage 1191. 
The pathogenesis of Chlamydia przeumoniae infec- 
tions has been studied using mouse models 120,211. 
When Chlamydia pneumoniae is given intranasally, acute 
infection with polymorphonuclear leukocytes in the 
lungs is seen only after massive challenge doses. Other- 
wise a silent pneumonitis with a clear histologic picture 
of mononuclear inflammation around bronchioles and 
vessels develop without overt illness. Repeated inocula- 
tions aggravate this inflammation temporarily, but the 
presence of the agent is difficult to demonstrate by 
isolation [22]. The demonstration of nucleic acids by 
polymerase chain reaction (PCR) gives, however, 
a positive finding and cortisone treatment, after 
alleviating inflammation, makes isolation of the agent 
possible [23]. Chlamydia pneumoniae is also demonstrable 
after intranasal challenge in the blood circulation, 
alveolar and peritoneal macrophages, and the liver and 
spleen, pointing to a disseminated infection 1241. 
Upper respiratory tract carriage has been described 
[25,26], and there is a possibility that carriers do not 
develop antibody responses or, if they do, only after 
a prolonged period. Pneumonias due to Chlamydia 
pneumoniae haw been described in infants [27], and 
from Japan there is a report of an epidemic in day- 
care centres [28]. However, in industrialized countries 
antibodies usually start to appear when children enter 
school [29, 301. In a recent Finnish study on childhood 
pneumonias, the youngest patient with a Chlamydia 
pneumoniae infection was 7 years old, and the majority 
of patients were over 10 years of age (Korppi et al, 
unpublished data). Other respiratory syndromes associ- 
ated with Chlamydia pneumoniae are rhinitis, sinusitis, 
pharyngitis, otitis, and bronchitis. A recent review of 
Chlamydia peumoniae infections in children concen- 
trated on respiratory tract infections [31]. However, 
during a Chlamydia pneumoniae epidemic in northern 
Finland, only a third of the children presenting a 
seroconversion were hospitalized because of respiratory 
tract symptoms (Uhari et al, unpublished data). The 
disease picture in children can thus be quite variable 
and demands further study. 
Primary infection in young adults leads to pneu- 
monia in about 10% of cases [32]. This is usually a 
mild disease, but can be prolonged with a long 
convalescence. In young age groups, reinfections seem 
not to lead to pneumonias (321. However, reinfection 
pneumonias, especially in elderly patients with under- 
lying diseases, can be very severe 1331. One possibility 
is that when the resistance to infection has decreased 
enough to allow the agent to invade the lungs, or 
the invading strain is different enough to be able to 
colonize the lungs, partial immunity can lead to hyper- 
sensitivity reactions typical of all chlamydia1 infections. 
The role that Chlamydia pneumoniae plays in other 
acute respiratory tract infections is still under study. In 
adults, it has been associated with 0.5-7'% of pharyn- 
gitis 134,351 cases (the last figure during an epidemic), 
and 5-100/;, of acute bronchitis cases. Sinusitis and otitis 
in adults have also been reported, but wider studies are 
so far lacking. 
Mixed infections are coninion in Chlamydia p i m -  
rnoniae infections. In the studies on Finnish children, 
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half or even the majority of patients have had a 
concomitant infection caused by another pathogen; 
virus, mycoplasma or bacterium. Similarly, during an 
epidemic in North Finland, nearly half of the 
Chlamydia pneumoniae pneumonias were combined 
with invasive pneumococcal infections [36]. Chlamydia 
pneumoniae has a ciliostatic effect [37], which in these 
cases may help pneumococci carried in the upper 
respiratory tract to invade deeper layers. These double 
infections were more severe than usual and the response 
to antibiotics effective against the pneumococcus only 
was poor [38]. One should not be satisfied when one 
pathogen is diagnosed, but always keep in mind the 
possibility of mixed infection. 
LABORATORY DIAGNOSIS OF ATYPICAL PATHOGENS 
Serology has traditionally been used to diagnose in- 
fections caused by atypical pathogens. Antigens and 
complete kits for antibody assays are commercially 
available from several sources. The most serious dis- 
advantage is the need to demonstrate a seroconversion 
in the majority of the cases. This delays the diagnosis 
and is then of no aid to the clinician treating the acutely 
ill patient. Attempts have been made to overcome this 
delay by the demonstration of IgM antibodies in the 
acute phase or by using ‘diagnostic’ high titers in the 
first serum sample. The pitfalls are the lack of IgM 
in reinfections and the uncertainty of the diagnostic 
value of high titers in acute diseases caused by several 
atypical agents. Serology, even though inadequate, has 
remained the main diagnostic tool in mycoplasmal and 
chlamydia1 pneumonias as well as in Q fever. 
Culture of the atypical pathogens demands special 
media not widely used in microbiology laboratories 
or, in the case of obligatory intracellular pathogens, 
cultured living cells in specialized units. Moreover, 
Coxiella burnetti and Chlamydia psittaci present dangers 
to laboratory workers handling the agent, and even 
Chlamydia pneumoniae has caused laboratory-acquired 
pneumonias [39]. In legionellosis, however, culture is a 
standard diagnostic procedure [40]. It should also be 
attempted in Chlamydia pneumoniae infections in order 
to obtain information on disease associations and strain 
variability of this newly recognized pathogen. 
Antigen detection in respiratory tract infections 
has been utilized mainly in viral infections, with good 
success. Its use in the case of atypical bacterial patho- 
gens has not been as rewarding. Moreover, techniques 
based on immunofluorescence demand experience and 
patience from the reader, since numbers of pathogens 
are often limited and their reliable identification is 
difficult. Lack of commercially available reagents and 
luts is a problem in the diagnosis of uncommon atypical 
pathogens. However, in legionellosis, detection of 
antigen in urine seems to be a reliable diagnostic 
method [11,41]. In pneumonias, the presence ofbacterial 
components in the circulation, alone or in immune 
complexes, has been used successfully in the diagnosis 
of pneumococcal pneumonias [42], but has remained 
unstudied in the case of atypical pathogens. These types 
of complex are commonly, seen, however, in chronic 
Chlamydia pneumoniae infections, which lessens their 
diagnostic value in acute infections, especially in elderly 
males with arteriosclerotic lesions [43]. 
Nucleic acid (NA) detections seems to be the diag- 
nostic method of the future for atypical respiratory 
pathogens. The commercial kit for M .  pneumoniae 
direct NA detection is no longer available, but diag- 
nostic companies are developing kits based on NA 
amplification for Legionella spp., M .  pneumoniae and 
Chlamydia pneumoniae. These, whether based on the 
polymerase or ligase chain reaction, would provide a 
sensitive and specific diagnosis for these pathogens in 
24 h. This would finally give a firm basis for a rationally 
targeted therapy. 
TREATMENT 
Table 3 shows the recommended treatment for infec- 
tions caused by atypical pathogens. The therapeutic 
response of bacterial atypical pathogens to p-lactam 
antibiotics and aminoglycosides is lacking or marginal. 
The drugs used are tetracyclines, macrolides, and 
azalides. Time will tell how much the advent of newer 
quinolones will alter these recommendations. Pro- 
longed treatment of 2-4 weeks has been used in 
legionellosis and in Chlamydia pneumoniae pneumonias. 
The possibility of mixed infections should always be 
kept in mind. 
Table 3 Main groups of drugs currently used for atypical 
pathogens 
Pathogen Preferred drugs Also effective 
Legionella spp. Erythromycin Quinolone? 
(+ rifampicin) 
Mycoplasma 
pneumoniae Erythromycin Macrolide/azalide 
Quinolone 
Chlamydia spp. Tetracycline Macrolide/azalide 
Erythromycin Quinolone 
Coxiella burnetti Doxycycline/ Quinolone 
< 
tetracycline 
Respiratory syncytial 
virus Ribavirin aerosol 
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CHRONIC SEQUELAE DUE TO ATYPICAL 
RESPIRATORY PATHOGENS 
Appropriate therapy can be efficient in preventing 
long-term sequelae caused by some of these atypical 
pathogens. Q fever endocarditis is a feared com- 
plication, which often leads to valvular operations or 
drug therapy for the rest of the patient’s life 1441. 
Recently discovered Chlamydia pneumoniae seems to be 
associated with complications of unexpected severity 
and ubiquity. Signs of chronic Chlamydia pneumoniae 
infection have been found in both childhood [45] 
and adult-onset [16] asthma, chronic bronchitis [47], 
and sarcoidosis [48]. Most surprising is its association 
with arteriosclerosis, the leading cause of death in 
industrialized countries. Markers of chronic Chlamydia 
yneumoniae infections are found in acute myocardial 
infarction [49,50], and they have repeatedly been 
shown to be a risk factor for cardiac events [51,52]; and, 
finally, the pathogen has been demonstrated in athero- 
sclerotic lesions 153,541. Animal experiments have been 
positive [55,56], as have preliminary intervention trials 
[57,58]. It may be possible that appropriate treatment 
of Chlavnydin pneumoniae respiratory infection in the 
acute phase prevents infection from progressing to a 
chronic state, which can be much more difficult to 
cure. This would demand acute diagnosis and targeted 
therapy for atypical pneumonias. 
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